Vivos Therapeutics (VVOS) Income from Continuing Operations (2020 - 2026)

Vivos Therapeutics (VVOS) has 7 years of Income from Continuing Operations data on file, last reported at 7751000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 100.6% year-over-year to 7751000.0 in Q1 2026; TTM through Mar 2026 was 25118000.0, a 122.38% decrease from a year earlier, with the FY2025 full-year figure at 21230000.0, down 89.66% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 7751000.0, down from 6954000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for VVOS reached as high as 9367000.0 in Q4 2023 and fell as low as 7751000.0 in Q1 2026.
• Historically, Income from Continuing Operations has averaged 3769352.94 across 5 years, with a median of 5013000.0 in 2025.
• Across the five-year window, Income from Continuing Operations jumped 251.35% in 2023 and plunged 159.74% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 6189000.0 in 2022, then soared by 251.35% to 9367000.0 in 2023, then plunged by 130.8% to 2885000.0 in 2024, then slumped by 141.04% to 6954000.0 in 2025, then decreased by 11.46% to 7751000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 7751000.0 in Q1 2026, 6954000.0 in Q4 2025, and 5400000.0 in Q3 2025.